z-logo
open-access-imgOpen Access
Clinical pharmacology of moxalactam in patients with malignant disease
Author(s) -
E. Estey,
Susanne Weaver,
Dah Hsi Ho,
Gerald P. Bodey
Publication year - 1981
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.19.4.639
Subject(s) - moxalactam , urine , intramuscular injection , medicine , pharmacokinetics , latamoxef , half life , microgram , pharmacology , serum concentration , chemistry , cephalosporin , antibiotics , biochemistry , in vitro
Pharmacological studies of moxalactam were conducted with 37 cancer patients. Intramuscular administration of 500 mg of moxalactam to 10 patients produced a mean peak serum concentration of 12.4 micrograms/ml. The serum terminal-phase half-life was 3.9 h. Intravenous administration of 500 mg of moxalactam over 5 min to the same 10 patients produced a mean serum concentration of 42.0 micrograms/ml at 15 min, which decreased to 3.3 micrograms/ml at 6 h. A dose of 1 g of moxalactam was given in an identical manner to the same 10 patients. The mean serum concentration was 69.7 micrograms/ml at 15 min and 7.4 micrograms/ml at 6 h. The mean proportions of a drug recovered in the urine by 12 h after administration were 59% after the intramuscular dose and 61 and 55% after the single intravenous doses. Multiple-dose intravenous studies were also conducted. The serum terminal-phase half-life varied from 2.0 to 3.2 h. Continuous infusion studies were performed by up to 9 days by using a loading dose of 1 g over 0.5 h, followed by 2 g every 6 h. Serum concentrations were maintained at about 30.0 micrograms/ml during the study period.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here